Clinical trials
Phase 1/2 Cholangiocarcinoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
56 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 4 |
| 2015 | 2 |
| 2017 | 2 |
| 2018 | 6 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 9 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 6 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Recruiting | 13 |
| Terminated | 12 |
| Unknown status | 7 |
| Active, not recruiting | 4 |
| Not yet recruiting | 2 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Zurich | 3 |
| National Cancer Institute (NCI) | 2 |
| TCR2 Therapeutics | 2 |
| Tango Therapeutics, Inc. | 2 |
| TransThera Sciences (Nanjing), Inc. | 2 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
| Alaunos Therapeutics | 1 |
| Alentis Therapeutics AG | 1 |
| Amgen | 1 |
| Arvinas Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cholangiocarcinoma | 56 |
| Biliary Tract Neoplasms | 12 |
| Stomach Neoplasms | 12 |
| Carcinoma, Non-Small-Cell Lung | 10 |
| Colorectal Neoplasms | 10 |
| Pancreatic Neoplasms | 10 |
| Gallbladder Neoplasms | 9 |
| Breast Neoplasms | 8 |
| Bile Duct Neoplasms | 7 |
| Endometrial Neoplasms | 7 |
Trials
Showing 26 to 50 of 56. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.